Success Stories: Cancer Research Scientist Secures NIW Approval in Less Than Two Months with Premium Processing

Client’s Testimonial:

“Thank you for your message. I am also pleased to work with you on this process.”

On April 1^st, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Visiting Researcher in the Field of Cancer Pathology (Approval Notice).

General Field: Cancer Pathology

Position at the Time of Case Filing: Visiting Researcher

Country of Residence at the Time of Filing: Japan

Approval Notice Date: April 1^st, 2025

Processing Time: 1 month, 24 days (Premium Processing Requested)

Case Summary:

At North America Immigration Law Group, we are proud to celebrate another rapid success story. A highly accomplished cancer researcher recently obtained I-140 NIW (National Interest Waiver) approval in just 1 month and 24 days through direct Premium Processing, thanks to her groundbreaking work and our dedicated petition strategy.

Client’s Field and Research Focus

Our client is a specialist in cancer pathology. Her proposed endeavor focuses on developing advanced diagnostic and therapeutic approaches for cancer through biomarker identification and optimized combination therapies. Her work aims to enhance early detection, personalize treatment plans, and improve survival outcomes for cancer patients.

Currently, she is engaged in cancer research and plans to continue developing innovative solutions in the biotech and pharmaceutical industry.

Petition Category and Achievements

Filed under the EB-2 NIW category, her case stood out based on:

● 11 peer-reviewed journal articles and 13 first-authored conference abstracts.
● 131 total citations according to Google Scholar, reflecting her wide impact in the academic community.
● Completed 3 peer reviews for academic journals in the field of dental sciences. Recognition for high-impact research, with two of her articles ranked among the top 20% most cited papers in Clinical Medicine for their respective years.
● Previous research funding from prestigious organizations such as the Japan Society for the Promotion of Science (JSPS) and the Ministry of Education, Culture, Sports, Science and Technology (MEXT).

Her publications appeared in prominent journals like Acta Neuropathologica Communications and Cancers, highlighting her distinguished position in her field.

Demonstrating National Importance

We demonstrated how her research supports the United States’ public health and economic interests by:

➔ Addressing cancer, one of the leading causes of death in the U.S., and advancing early detection strategies that could save billions in healthcare costs.
➔ Contributing to innovations in the U.S. cancer therapeutics market, a sector projected to grow to over $120 billion by 2032.
➔ Enhancing biomedical research and precision medicine, in alignment with national priorities to improve health outcomes and drive economic resilience.

An excerpt from one of her recommendation letters eloquently captured her impact:

“[Client] has significantly advanced our understanding of cancer biomarkers and optimized combination therapies, providing critical insights that are essential for developing effective treatments and reducing the cancer burden in the United States.”

Outcome

Through her strong research profile, significant peer recognition, and our expertly crafted legal arguments, the client’s NIW petition was approved swiftly without any requests for additional evidence.

We are honored to have played a part in her success story and are confident she will continue to contribute meaningfully to medical innovation and public health advancements in the United States.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.